How to Help Your Patients Find Fiasp in Stock: A Provider's Guide

When a patient calls your office saying they can't find their Fiasp anywhere, it puts your care team in a difficult position. The ongoing shortage of Fiasp FlexTouch pens has made this scenario common since 2024. Having a systematic approach — from prescription writing to patient-facing tools — can dramatically reduce the burden on both your staff and your patients.

This guide provides concrete, actionable strategies your practice can implement today.

Understand the Shortage Landscape Before Prescribing

The first step is knowing which Fiasp formulations are affected. As of early 2026:

• FlexTouch pen: Most constrained; intermittent supply since April 2024
• PenFill cartridge: More consistently available; consider defaulting to this format
• 10 mL vial: Most widely available format; cost-effective for patients without device preference
• PumpCart: Availability varies; confirm with pharmacy before prescribing for CSII patients

Write Flexible Prescriptions to Reduce Access Delays

One of the most impactful things you can do is write prescriptions that give pharmacists flexibility to dispense an available formulation. Strategies include:

• Write "Fiasp FlexTouch OR PenFill cartridge OR vial" when all formats are therapeutically equivalent for the patient
• Include a note: "May substitute Fiasp PenFill cartridge if FlexTouch unavailable" — this prevents unnecessary prior authorization delays
• For patients without a strong preference for pens, consider defaulting to vials — they are cheaper, more widely available, and functionally equivalent
• If Fiasp is consistently unavailable, write a therapeutic alternative prescription alongside a note to try Fiasp first — this prevents delays if the first choice isn't found

Direct Patients to medfinder to Find Pharmacy Stock

Rather than having your staff spend time calling pharmacies, direct patients to medfinder. With medfinder, patients provide their medication, dosage, and zip code, and medfinder calls pharmacies in their area to find which ones have Fiasp in stock — then texts them the results.

This is particularly valuable for:

• Patients in rural areas with few pharmacy options nearby
• Elderly patients who struggle to make multiple calls and navigate hold queues
• Patients who have already been turned away by multiple pharmacies

Educate Patients on All Available Fiasp Formats

Many patients are unaware that Fiasp comes in multiple formats. When a patient calls saying the pen is out of stock, your staff can educate them:

• Fiasp PenFill cartridges can be used with a reusable NovoPen device. If the patient doesn't have one, the office can prescribe it, or the patient can ask the pharmacy about device loan programs.
• Fiasp 10 mL vials require standard U-100 syringes. Provide brief injection technique counseling if a patient is switching from a pen to vial.

Help Patients Navigate Insurance and Prior Authorization

During shortages, patients may need to switch to a different formulation or product than what their insurance previously approved. Your team can help by:

• Filing prior authorization appeals that cite the shortage as a medical necessity reason for the alternative product
• Checking whether the alternative insulin is on a preferred tier to minimize patient cost
• For Medicare patients: Fiasp is subject to Medicare negotiated pricing effective 2026, and patients pay no more than $35/month for covered insulin under the IRA

Key Savings Programs to Share with Patients

If patients are facing cost barriers on top of access challenges, point them toward:

• Novo Nordisk Savings Card: As low as $35/month for commercially insured patients; covers up to 3 vials or 2 packs of pens; 1 free pack of needles included. Enroll at novocare.com.
• NovoCare Patient Assistance Program: Free Fiasp for qualifying uninsured/underinsured patients; call 1-866-310-7549 or visit novocare.com.
• GoodRx/SingleCare: Coupon cards that can reduce Fiasp vial cost to approximately $63–$78 at participating pharmacies, regardless of insurance status.

When to Consider a Full Therapeutic Substitution

If a patient has exhausted all Fiasp format options in your area, consider a transition to Lyumjev (ultra-rapid, meal-start dosing) or NovoLog (same molecule, unit-for-unit switch). Full clinical guidance on therapeutic alternatives is covered in: Fiasp Shortage: What Providers Need to Know in 2026.

For more tools to support your patients in finding and affording their medications, visit medfinder for providers.